Journal of Clinical Pharmacology

Article	Citations
	93
	70
Protecting Mothers and Babies Through Research	38
Issue Information	38
Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study	31
Maternal–Fetal Drug Development: An Industry Perspective	30
What Is the Role of Sex‐Related Differences in the Effectiveness and Safety of Biological Drugs Used in Patients With Severe Asthma?	25
	24
Low Early Antifactor Xa Target Achievement Rate of Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients in Intensive Care	23
Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects	23
Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion	22
Clinical Lactation Studies of Neuropsychiatric Medications: Clinical Pharmacology and Labeling Considerations	22
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters	21
Issue Information	21
Pharmacokinetics and Safety of a Novel Extended‐Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder	21
Challenges in Conducting Therapeutic Trials in Pregnancy: Emphasizing Recent Lessons Learned	21
Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A	21
Exploring Factors Affecting the Occurrence of Hypersensitivity Reactions Induced by Nonionic Iodine Contrast Media	21
Comment: Cerebrospinal Fluid Pharmacokinetics of Nicardipine Following Intrathecal Administration in Subarachnoid Hemorrhage Patients	20
Issue Information	20
Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients with Moderate‐to‐Severe Renal Impairment	18
Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events	18
	18
Comparison of Misoprostol and Evening Primrose Oil on Cervical Preparation Before Gynecological Surgery	17
Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework	17

Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration	16
Issue Information	16
Pharmacokinetic and Pharmacodynamic Modeling Analysis of Delpazolid (LCB01‐0371) in Adult Patients with Pulmonary Tuberculosis	15
Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates	15
Pharmacological Enhancement of Radionuclide Therapy Using Radiopharmaceutical–Drug Combinations in Oncology	15
Determination of Vatiquinone Drug‐Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation	14
The Role of the Mesencephalic Astrocyte‐Derived Neurotrophic Factor in Patients in Intensive Care Units Receiving Voriconazole Therapy	14
Contemporary Use of Oral Inotropes in the Outpatient Treatment of Heart Failure: Analysis of a Japanese Nationwide Database	14
Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity	14
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic–Pharmacodynamic Framework for Obicetrapib	14
Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders	13
Learnings from Approved Antibody‐Drug Conjugates: Clinical Pharmacology Perspectives	13
Effectiveness and Safety of Histamine H2 Receptor Antagonists: An Umbrella Review of Meta‐Analyses	13
Using Real‐World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and Infants	13
Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials	13
Physiologically Based Pharmacokinetic Modeling of Caffeine in Preterm Neonates: Influence of Renal Function and Impairment on Dosing	12
Population Pharmacokinetics and Dosing Simulations of Pentobarbital in the Pediatric Population	12
A Phase I Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Liposomal Bupivacaine for Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy	12
Pharmacokinetics of Antiretroviral Agents in Pregnant Individuals Living With HIV: Current Status and Considerations for Study Design and Interpretation	12
Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer	12
	12
Issue Information	11
Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists	11
Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis	11
An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?	11
Comparison of Two Dexmedetomidine Administration Strategies on the Incidence of Postoperative Respiratory Complications: A Retrospective, Inverse Probability of Treatment Weighted Study	11
Antidepressants and Antipsychotics in Human Pregnancy: Transfer Across the Placenta and Opportunities for Modeling Studies	11
Characterization of Immune Checkpoint Inhibitor–Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System	11
The Impact of Standard Versus Weight‐Based Maintenance Dosing of Fosphenytoin on Achieving Therapeutic Drug Levels	11
Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy	11
Efficacy of Bile Acid Sequestrants in the Treatment of Bile Acid Diarrhea: A Meta‐Analysis of Randomized Controlled Trials	10
Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors	10
Quantitative Comparison of the Predictive Accuracy of Warfarin Pharmacogenetic Dosing Algorithms Derived From Population Data of Different Ethnicities in the Chinese Population	10
A Retrospective Cohort Study Examining the Effects of Anti‐PD‐1 Antibody in Combination with Apatinib in Patients Previously Treated for Her2‐Negative Advanced Gastric/Gastroesophageal Junction Cancer	10
Influence of Calcineurin Inhibitors and Genetic Polymorphism of Transporters on Enterohepatic Circulation and Exposure of Mycophenolic Acid in Chinese Adult Renal Allograft Recipients	10
Issue Information	10
Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors	10
Understanding and Streamlining Dose Finding: From Dose Simulation to Dose Estimation	10
Correction to “Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery with Cardiopulmonary Bypass”	10
Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023	10
Characterizing Associations of QTc Interval with Nocturnal Glycemic Control in Children with Type 1 Diabetes	10
In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor	10
Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations	9
A Phase 1 Randomized Study: Garadacimab Pharmacokinetics, Safety, and Tolerability After Administration via Autoinjector/Pre‐Filled Pen Versus Pre‐Filled Syringe in Healthy Participants	9
Back Pedaling on Baclofen: Highlighting Concerns Surrounding Baclofen use in Phenibut Withdrawal	9
	9
Exposure–Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia	9
Regulatory Framework for Drug Development in Rare Diseases	9
Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM	9
2023 JCP Peer Reviewer List	9

Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies	9
JCP 2022 Reviewer Thank‐You List	9
Clinical Consequences of Altered Drug Disposition in Obesity: Call for Change	9
Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation	9
Issue Information	9
	9
Population Pharmacokinetic Modeling of Intravenous Topiramate in Patients with Epilepsy or Migraine	8
Comment on “Understanding Atomoxetine Exposure Variability in Children and Adolescents with ADHD through Population Pharmacokinetics”	8
Reply to: Comment: Cerebrospinal Fluid Pharmacokinetics of Nicardipine Following Intrathecal Administration in Subarachnoid Hemorrhage Patients	8
Clinical Pharmacology Considerations on Recombinant Adeno‐Associated Virus–Based Gene Therapy	8
Immunogenicity of Cemiplimab: Low Incidence of Antidrug Antibodies and Cut‐Point Suitability Across Tumor Types	8
Capillary Filtration of Plasma Is Accelerated During General Anesthesia: A Secondary Population Volume Kinetic Analysis	8
First‐in‐Human Study of a Long‐Acting GLP‐1 Receptor Agonist (TE‐8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus	8
Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma	8
Missed Opportunities: Intravenous versus Oral Antibiotic De‐escalation for Treatment of Lower Extremity Osteoarticular Infections	8
Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug‐Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors	8
Influence of Dapagliflozin Dosing on Low‐Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus: A Systematic Literature Review and Meta‐Analysis	8
Optimization of Voriconazole Dosing Regimens Against Aspergillus Species and Candida Species in Pediatric Patients After Hematopoietic Cell Transplantation: A Theoretical Study Based on	8
Correction to “The Association Between Concurrence of Infection and the Onset of Severe Eruption or Liver Injury in Patients Using Antipyretic Analgesics: A Matched, Nested Case‐Control Study”	8
Mind the Gap: Unraveling the Pharmacokinetic Variability of Δ9‐Tetrahydrocannabinol (THC)	8
Preclinical and Clinical Pharmacokinetics of JNJ‐75220795, an siRNA Therapeutic Targeting PNPLA3, for Metabolic Dysfunction‐Associated Steatohepatitis	8
Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment: Role and Opportunities	8
Physiologically Based Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Analysis for Ceftriaxone Dosing in Pregnant Women: Model Development and Clinical Applications	8
Issue Information	8
Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation	8
Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide	8
Expansion of a Pharmacokinetic Model for Diazepam to Characterize Real‐World IV and Oral Data in Children With and Without Obesity	8
Randomized, Placebo‐Controlled, First‐in‐Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Ad	8
In Silico Modeling for Ex Vivo Placental Transfer of Morphine	8
Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants	8
Precision Pharmacokinetics of Quetiapine: A Physiologically Based Model Incorporating Liver Cirrhosis and CYP3A4 Polymorphisms	7
Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5‐Year Retrospective Cohort Study	7
Issue Information	7
	7
Myelosuppression Caused by Nanoparticle Albumin‐Bound Paclitaxel in the Northern Chinese Population and the Role of Body Composition	7
Once‐ Versus Twice‐Daily Tacrolimus Therapy: Does Improved Adherence Lead to Better Efficacy?—A Pharmacokinetic Perspective	7
Street Pharmacology: Toxico‐Dermatology of Injection Drug Use	7
Issue Information	7
Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide–Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma	7
Antibody Transfer From Mother to Fetus/Infant: An Opportunity for Model‐Informed Precision Medicine	7
Limited Sampling Strategy for Predicting the Area under Plasma Concentration–Time Curve of Nadolol in Healthy Subjects	7
Issue Information	7
	7
Issue Information	7
Five‐Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture	7
Influence of Disease Type and Activity on Adalimumab Exposure in Children with Inflammatory Rheumatic Diseases	7
Physiologically Based Pharmacokinetic Modeling of Vancomycin in Critically Ill Neonates: Assessing the Impact of Pathophysiological Changes	7
From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment	7
Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine–Naloxone With a Focus on the Unhoused Population	7
Changing Trajectories of Alanine Aminotransferase and Risk of Antituberculosis Drug‐Induced Liver Injury in Chinese Patients: A Cohort Study	7
Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals	7
Issue Information	7
No QTcF Prolongation with Sepiapterin: Results From a Thorough QT Study in Healthy Subjects at Therapeutic and Supratherapeutic Doses	7
	7
Over‐the‐Counter Epinephrine for Asthma Treatment: Too Much Risk for Too Little Benefit	7
Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products	6
	6
Comparison of Clinical Effectiveness Between Ambroxol and N‐Acetylcysteine in Surgical Patients: A Retrospective Cohort Study	6
Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)‐Negative Breast Cancer	6
Population Pharmacokinetics and Dose Simulation of Levetiracetam in Patients with Epilepsy: Influence of Renal Function and Phenytoin Co‐Administration	6
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia	6
Impact of Lisinopril on Cardiometabolic Risk Factors in Sisters of Women With Polycystic Ovary Syndrome	6
Study of the Association of Single Nucleotide Polymorphisms in Candidate Genes With Sevoflurane	6
Reframing Non‐Traditional PharmD Career Opportunities Across Drug Development, Regulatory, and Academia	6
A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End‐Stage Kidney Disease on Hemodialysis	6
Genetic Polymorphism as a Possible Cause of Severe Postoperative Pain	6
Evaluation of Cannabis Per Se Laws: A Semi‐Mechanistic Pharmacometrics Model for Quantitative Characterization of THC and Metabolites in Oral Users	6
A Retrospective Analysis of PK and Response of Oral Ibuprofen in the Treatment of a Patent Ductus Arteriosus in Extremely Low Gestational Age Neonates	6
Issue Information	6
Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling	6
Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies	6
DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes	6
Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis	6
Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data	6
Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease	6
Modification of Vancomycin Dosing in Cardiac Surgery With Cardiopulmonary Bypass	6
Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study	6
Vaginal Misoprostol Pharmacokinetic Changes in Obese Parturient Women Who Presented Labor Induction Failure	6
In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation	6
	6

In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers	6
	6
Intranasal Naloxone During Recurrent Exercise in Individuals with Type‐1 Diabetes Mellitus: Evaluation of the Clinical Predictors of Pharmacokinetics and Exposure–Response	6
Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects	6
Issue Information	6
US FDA Postmarketing Requirements and Commitments: A Systematic Assessment of Clinical Pharmacology Studies and Their Impact on US FDA Prescribing Information	6
Physiologically Based Pharmacokinetic Modeling of Lemborexant: Exploration of Doses for Populations with Hepatic Impairment	6
In Memoriam: Varsha Bhatt‐Mehta, PharmD, MS, FCCP	6
An Intravenous Study with the Radiolabeled sGC Stimulator Frespaciguat to Assess PK, Metabolism, and Mass Balance	6
Correction to “A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants With End‐Stage Kidney Disease on Hemodialysis”	5
The Role of Pain Medications in Modulating Peripheral Nerve Injury Recovery	5
Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants	5
Evaluating Tranexamic Acid Dosing Strategies for Postpartum Hemorrhage: A Population Pharmacokinetic Approach in Pregnant Individuals	5
ChatGPT and Factual Knowledge Questions Regarding Clinical Pharmacy: Response to Letter to the Editor	5
Population Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients With Fabry Disease and Moderate to Severe Renal Function Impairment	5
Impaired Cardiometabolic Effects of Bromocriptine in Men With Early‐Onset Androgenic Alopecia	5
Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT3 Antagonist Antiemetic Drugs	5
The Pharmacokinetics and Relative Bioavailability of a Mini‐Tablet of Mercaptopurine, a Novel Formulation for Use in Children with Acute Lymphoblastic Leukemia	5
Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure–Response	5
How to Replace the TQT Study—The Use of Concentration‐QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation	5
Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia	5
Drug Combination Modeling: Methods and Applications in Drug Development	5
Population Pharmacokinetics of Caffeine in Infants with Hypoxic‐Ischemic Encephalopathy: A Phase I, Dose‐Escalating Trial	5
Lack of Modulation of In Vivo Activity of Organic Anion Transporters 1 and 3 in Pregnancy Using Furosemide as a Probe	5
	5
Issue Information	5
Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti‐Tuberculosis Drug‐Induced Liver Injury	5
Pharmacogenetic Approaches to Optimize Bioequivalence Studies in Generic Drug Development	5
Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use	5
Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure‐Tumor Growth Inhibition Model: Apitolisib (Dual PI3K	5
Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models	5
The Impact of Survival Benefit and Study Design on FDA Approval for Anticancer Drugs Over the Past Decades	5
Mechanistic Framework to Predict Maternal‐Placental‐Fetal Pharmacokinetics of Nifedipine Employing Physiologically Based Pharmacokinetic Modeling Approach	5
Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes	5
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer	5
ACCP Position Statement on Unregulated Psychotropic Products	5
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (	5
Construction and Validation of a Predictive Model for the Risk of Anti‐Tuberculosis Drug‐Induced Liver Injury Based on Machine Learning Algorithms	5
Drug Administration via Enteral Feeding Tubes: A Landscape Analysis of Information in Drug Product Labeling	5
Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma	5
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta‐Analysis	5
	5
From Fragmented Data to Integrated Drug Development in Asphyxiated Neonates Undergoing Therapeutic Hypothermia	4
Relative Bioavailability of Omaveloxolone When Capsules Are Sprinkled Over and Mixed in Applesauce Compared With Administration as Intact Omaveloxolone Capsules: A Phase 1, Randomized, Open‐Label, Sin	4
Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA‐Labeled Dosing Frequency of RHB‐105 Low‐Dose Rifabutin Triple Therapy for Helicobacter pylori Eradic	4
Pharmacokinetics of Atorvastatin and Metformin after Coadministration with Islatravir in Healthy Adults	4
	4
Obesity Considerations in Pediatric Drug Development, 2016–2021	4
Issue Information	4
Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population	4
In Memoriam	4
Statin Drug‐Drug Interactions: Pharmacokinetic Basis of FDA Labeling Recommendations and Comparison Across Common Tertiary Clinical Resources	4
Pharmacokinetic Characterization of Iopamidol and Iohexol for Optimizing Measured Glomerular Filtration Rate Assessment in Clinical Practice and Drug Development	4
Hypokalemia and Hyponatremia in Adult Patients Receiving Voriconazole Therapeutic Drug Monitoring	4
Population Pharmacokinetic Modeling and Stochastic Simulations to Support Pediatric Dose Selection of Pimavanserin	4
Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model	4
A Randomized Crossover Clinical Study to Assess the Effect of Oral Nicotine Pouches Used for Different Durations on Plasma Nicotine Pharmacokinetics in Healthy Oral Pouch Consumers	4
Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam	4
	4
ACCP Position Statement on Hydration and Vitamin Infusion Clinics	4
	4
Value of Assessing 1‐Hydroxymidazolam in Drug‐Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A	4
Prescription of Oral Contraceptives by Licensed Pharmacists in the USA	4
From Small Data to Big Decisions: How Clinical Pharmacology Shapes Rare Disease Development	4
Incidence of Adverse Events Induced by Atropine in Myopic Children: A Meta‐Analysis	4
Urate‐Lowering Drugs and Muscle Injury: A Systematic Review and Network Meta‐Analysis	4
Celebrating the 65th Anniversary of the Journal of Clinical Pharmacology	4
Pharmacokinetics, Safety, and Tolerability of GS‐1427, an Oral Prodrug of a Potent and Selective α4β7 Integrin Inhibitor, in Healthy Participants	4
Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib	4
Pharmacokinetics and Safety of Imeglimin in Japanese Patients With Impaired Renal Function	4
Genotype‐Guided Model for Prediction of Tacrolimus Initial Dosing After Lung Transplantation	4
Optimal Design of Drug–Drug Interaction Studies for the GLP‐1 Receptor Agonist Drug Class for Weight Management: Closing a Potential Data Gap	4
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist	4
	4
The Journal of Clinical Pharmacology : 65 Years of History	4
Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	4
Issue Information	4
In Memoriam: Barry Dvorchik, BS, PhD, FCP	4
Drug‐Related Adverse Reactions in Pediatric Inflammatory Bowel Disease	4
Pharmacokinetics, Safety, and Tolerability of Anti‐miR‐17 Oligonucleotide RGLS4326 in Healthy Adult Subjects	4
Exogenous Melatonin and Sleep Quality: A Scoping Review of Systematic Reviews	4
Correlations of PCSK9 and LDLR Gene Polymorphisms and Serum PCSK9 Levels With Atherosclerosis and Lipid Metabolism in Patients on Maintenance Hemodialysis	4
Simultaneously Predicting Pharmacokinetics of Loratadine and Desloratadine in Children Using a Whole‐Body Physiologically Based Pharmacokinetic Model	4